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Abstract
Background: HIV–infected persons are at increased risk of pneumonia, even with highly active antiretroviral treatment
(HAART). We examined the impact of pneumonia on mortality and identified prognostic factors for death among HIV–
infected.
Methodology/Principal Findings: In a nationwide, population-based cohort of individuals with HIV, we included persons
hospitalized with pneumonia from the Danish National Hospital Registry and obtained mortality data from the Danish Civil
Registration System. Comparing individuals with and without pneumonia, we used Poisson regression to estimate relative
mortality and logistic regression to examine prognostic factors for death following pneumonia. From January 1, 1995, to
July 1, 2008, we observed 699 episodes of first hospitalization for pneumonia among 4,352 HIV patients. Ninety-day
mortality after pneumonia decreased from 22.4% (95% confidence interval [CI]: 16.5%–28.9%) in 1995–1996 to 8.4% (95% CI:
6.1%–11.6%) in 2000–2008. Mortality remained elevated for more than a year after hospitalization for pneumonia: adjusted
mortality rate ratio 5.38 (95% CI: 4.27–6.78), 1.80 (95% CI: 1.36–2.37), and 1.62 (95% CI: 1.32–2.00) for days 0–90, 91–365, and
366+, respectively. The following variables predicted mortality within 90 days following hospitalization for pneumonia
(adjusted Odds Ratios): male sex (3.77, 95% CI: 1.37–10.4), Charlson Comorbidity Index score $2 (3.86, 95% CI: 2.19–6.78); no
current HAART (3.58, 95% CI: 1.83–6.99); history of AIDS (2.46, 95% CI: 1.40–4.32); age per 10 year increase (1.43, 95% CI:
1.11–1.85); and CD4+ cell count #200 (2.52, 95% CI: 1.37–4.65).
Conclusions/Significance: The first hospitalization for pneumonia among HIV–infected individuals was associated with
elevated risk of death up to more than a year later. Use of HAART decreased the risk, independent of current CD4+ cell
count. Prognosis following pneumonia improved over calendar time.
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Introduction
Early in the HIV epidemic it was recognized that morbidity and
mortality due to pneumonia were higher in HIV-infected persons than
in the general population [1]. In 1993 the United States Centers for
Disease Control and Prevention categorized two or more episodes of
bacterial pneumonia as an AIDS-defining event [2]. The introduction
of highly active antiretroviral therapy (HAART) markedly reduced the
incidence of AIDS and death among HIV-infected persons [3,4,5],
and improved immune function also led to fewer pneumonia-related
hospitalizations [6,7]. However, more than a decade after the
widespread introduction of HAART in high-income countries, the
risk of pneumonia among HIV-infected persons remains high
compared to persons without HIV [7]. A better understanding of
modifiable prognostic factors for death after pneumonia could
potentially reduce mortality from this illness. In this cohort study we
estimated the impact of a first hospitalization for pneumonia on
mortality among Danish HIV patients, examined changes over
calendar time in mortality following hospitalization for pneumonia,
and identified prognostic factors for death following pneumonia.
Methods
Study design and setting
We conducted a nationwide, population-based cohort study
among HIV-infected persons in Denmark from 1995 to 2008.
Treatment for HIV infection in Denmark is restricted to 8
specialized centers. The Danish health care system provides free,
tax-supported medical care for all residents, including antiretro-
viral treatment of HIV.
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The DHCS has established a prospective, dynamic, nationwide,
population-based cohort of all HIV-infected individuals seen in
Danish HIV clinics since 1 January 1995. DHCS has been
described in detail elsewhere [8,9]. The study is ongoing, with
continuous enrolment of both newly diagnosed patients and
immigrants with HIV infection. Study data are updated annually
with information on antiretroviral treatment, development of
opportunistic infections and other AIDS-defining illnesses, and
laboratory data including plasma HIV RNA (viral load (VL)) and
CD4
+ cell count.
Danish Civil Registration System (CRS)
CRS is a national registry of all Danish residents, which
contains information on date of birth, sex, date of migration, and
date of death. A 10-digit personal registration number (CPR
number), assigned at birth, uniquely identifies each person since
1968. The CRS is updated within a week of a person’s birth,
death, or emigration. Use of the CPR number enables Danish
HIV clinics to avoid multiple registrations of the same patient and
allows tracking of deaths and persons lost to follow-up due to
emigration.
The Danish National Hospital Registry (NHR)
NHR contains information on all patients discharged from
Danish hospitals since 1977. Records for each hospitalization
include CPR number, hospital department, inpatient and outpa-
tient discharge diagnoses, and dates of admission and discharge.
Diagnoses are coded by the treating physician according to the
International Classification of Diseases, 8th revision (ICD-8) until
the end of 1993 and 10th revision (ICD-10) thereafter.
Identification of pneumonia
We identified the first hospitalization for pneumonia following
HIV diagnosis. We used the NHR to identify all hospital stays with
a discharge diagnosis of pneumonia using ICD-8 codes 471.x
(influenza with pneumonia), 480.x-486.x (pneumonia), 073.x
(ornithosis) and ICD-10 codes J11.0 (influenza with pneumonia),
J12.x–J18.x (pneumonia), A481.x, (ornithosis), or A709.x (legion-
ellosis). Thus, both community-acquired and hospital-acquired
pneumonias were included. The pneumonia diagnoses recorded in
the NHR were validated in a previous report [7]. Pneumonia
onset was defined as the date of hospital admission. Since we have
not validated pneumonia diagnoses in emergency room and
outpatient settings, outpatient diagnoses were not included. AIDS-
defining Pneumocystis jiroveci pneumonia was not counted as an
episode of pneumonia.
Study population
Our study population consisted of persons in DHCS who were
at least 16 years old on the date of HIV diagnosis and who had no
recorded hospitalization for pneumonia before entering DHCS.
Study subjects were followed from their registration in DHCS to
death, loss to follow-up or 1 July 2008, whichever came first.
Definitions
HAART was defined as either a 3-drug regimen that included a
non-nucleoside reverse transcriptase inhibitor, a protease inhibi-
tor, and/or abacavir; or a 2-drug regimen with a combination of a
non-nucleoside reverse transcriptase inhibitor and a boosted
protease inhibitor.
CD4
+ cell counts and viral load (VL) were estimated between
measurements by carrying forward the value from the most recent
measurement. Nadir CD4
+ cell count was defined as the lowest CD4
+
cell count ever measured for a given patient.
Comorbidity was assessed with the Charlson Comorbidity Index
(CCI). The index, which includes 19 major disease categories, has
been adapted and validated for use with hospital discharge data in
ICD databases for predicting short- and long-term mortality [10]. A
CCI score was computed for each patient based on all available
foregoing NHR discharge diagnoses. A previous AIDS diagnosis
(conferring 6CCI points)was not included inourcomputations [11].
Hepatitis C co-infection was defined as patients having at least 1
positive result on a hepatitis C virus (HCV)-antibody test or a
positive result on HCV RNA test.
The endpoint, defined a priori, was all-cause mortality following
the hospital admission date for pneumonia. Causes of death,
extracted from patient files and available in the DHCS database,
were divided into HIV-related causes (AIDS-defining illnesses and
bacterial infections, corresponding to ICD-10 codes A02, A07.2–
07.3, A15–19, A31, A81.2, B00, B20–25, B37–39, B45, B58, C46,
C53, C83.4,C83.9, F02.4, and J13–17 [pneumonia]), serious non–
AIDS causes (cardiovascular disease [i.e. myocardial infarction or
stroke], end stage renal and liver disease, COPD, and non-AIDS-
defining malignancies), unnatural causes (i.e. drug overdose,
suicide, accident) and other/unknown causes.
Statistical analyses
We first computed 30-day and 90-day cumulative mortality
following the first hospitalization for pneumonia and constructed
Kaplan-Meier survival curves, stratified into 3 calendar periods:
1995–1996 (‘‘pre-HAART era’’), 1997–1999 (‘‘early HAART
era’’), and 2000–2008 (‘‘late HAART era’’).
We then assessed the effect of a first hospitalization for
pneumonia on mortality. We compared the mortality rate in
persons who had no previous history of pneumonia (reference
group) with that of persons with a first hospitalization for
pneumonia within the last 0–90 days, within the last 91–365
days, and more than 365 days ago. Poisson regression analysis was
used to adjust for potential confounders. The following time-
dependent variables were forced into the model based on their
presumed association with pneumonia and/or effect on mortality:
CCI score (0–1/2+), age (10-year intervals), and CD4+ cell count
(continuous). Other variables were examined and included in the
final model if they changed the effect measure by 10% or more.
Constant variables were sex (male/female), hepatitis C coinfection
(yes/no), injection drug use (IDU) as presumed mode of HIV
infection (yes/no), and race (Caucasian/non-Caucasian). Time-
dependent variables were history of AIDS (yes/no), current
HAART (yes/no), years since entering the DHCS, and calendar
time period (1995–96 vs. 1997–2008). Causes of death were
tabulated for all four time periods.
Finally, we used logistic regression to identify prognostic factors
for 30-day and 90-day mortality following hospitalization for
pneumonia. In the unadjusted analyses we included all the
variables listed above as of the time of admission, as well as log-
transformed HIV RNA (continuous). In the adjusted analyses of
30-day and 90-day mortality we included all variables from the
unadjusted analyses in the models, except: nadir CD4+ cell count
because this variable and history of AIDS are interdependent
(adjustment for nadir CD4
+ cell count thus could cancel out the
effect of previous AIDS); IDU as mode of HIV exposure which is
interdependent with hepatitis C status; and HIV RNA which is
interdependent with use of HAART.
We used Stata software, version 9.2 (StataCorp, College Station,
TX, USA) for statistical analyses. The study was approved by the
Danish Data Protection Agency. In Denmark, a national board
HIV Mortality from Pneumonia
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Informed consent was waived. Informed consent was not required
by Danish law in order to conduct cohort studies.
Results
DHCS study population
Between 1 January 1995 and 1 July 2008, 699 episodes of an
initial hospitalization for pneumonia were observed among 4,352
persons who were at least 16 years old and had no recorded
hospitalization for pneumonia before entering the DHCS cohort.
Characteristics of persons in our study population at the time of
the initial hospitalization for pneumonia are shown in Table 1.
Less than half (43.3%) received HAART and the median CD4+
cell count was 281 cells/ml.
Impact of hospitalization for pneumonia on survival
among HIV patients
Overall 30-day risk of death after first hospitalization for
pneumonia was 6.4% (95% CI: 4.8%–8.5%) (see Figure 1). It was
7.9% (95% CI: 4.6%–13.5%) in 1995–1996, 7.6% (95% CI:
4.1%–13.6%) in 1997–1999, and 5.5% (95% CI: 3.7%–8.2%) in
2000–2008. Overall 90-day risk of death was 12.0% (95% CI:
9.8%–14.7%), decreasing from 22.4% (95% CI: 16.5%–28.9%) in
1995–1996 to 11.4% (95% CI: 7.0%–18.1%) in 1997–1999, and
to 8.4% (95% CI: 6.1%–11.6%) in 2000–2008.
The effect of first-time hospitalization for pneumonia on
mortality among all HIV-infected persons is shown in Table 2.
Adjusting for use of HAART, history of AIDS, years since entering
the DHCS, CCI score, age, and current CD4+ cell count, the
relative mortality during the first 90 days after an initial
hospitalization for pneumonia, compared to those with no previous
hospitalization for this indication, was 5.38 (adjusted mortality rate
ratio [MRRadj],95%CI:4.27–6.78). Mortality wasalsoelevated for
days 91–365 (MRRadj=1.80, 95% CI: 1.36–2.37) and days 366+
(MRRadj=1.62, 95% CI:1.32–2.00). Causesof death for persons in
all four time strata are presented in Table 3. Among those who died
within days 0–90, days 91–365, and after 365 days, 61.9%, 53.7%,
and 28.8%, respectively, had an HIV-related cause of death.
Prognostic factors for short-term mortality following
hospitalization for pneumonia
In the adjusted logistic regression analysis, the following
variables were associated with increased 30-day mortality after a
first hospitalization for pneumonia (Table 4): CCI score $2
(ORadj=4.07, 95% CI: 2.03–8.17), male sex (ORadj=3.86, 95%
CI: 1.05–14.2), no current HAART (ORadj=3.19, 95% CI: 1.42–
7.16), history of AIDS (ORadj=2.78, 95% CI: 1.34–5.78), latest
CD4+ cell count #200 cells/ml (ORadj=2.72, 95% CI: 1.28–5.78)
and age (ORadj=1.53 per 10 year increase, 95% CI: 1.11–2.12).
Variables associated with increased 90-day mortality were
(Table 5): CCI score $2 (ORadj=3.86, 95% CI: 2.19–6.78), male
sex (ORadj=3.77, 95% CI: 1.37–10.4), no current HAART
(ORadj=3.56, 95% CI: 1.83–6.99), previous AIDS (ORadj=2.46,
95% CI: 1.40–4.32), CD4+ cell count #200 (ORadj=2.52, 95%
CI: 1.37–4.65) and age (ORadj=1.43 per 10 year increase, 95%
CI: 1.11–1.85). Among patients on HAART neither the duration
of HAART use or HIV RNA (,50 vs. $50 copies/mL) were
protective (data not shown).
Discussion
This study found that short-term mortality after a first hospital-
ization for pneumonia among HIV-infected individuals decreased
from the pre-HAART to the late-HAART era. Despite this decrease
over time, an episode of hospitalization due to pneumonia remains
associated with an increased mortality among HIV patients.
P r o g n o s t i cf a c t o r sw e r em a l es e x ,a g e ,p r e - e x i s t i n gc o m o r b i d i t y ,l o w
CD4 cell count, older age, and absence of HAART treatment.
Several studies have shown that persons on HAART have a reduced
Table 1. Baseline charactaristics of HIV–infected individuals
at time of first admission for pneumonia.
Variable
Numbers
(N=699)
Median age, years (interquartile range) 42.2 (35.2–50.1)
Sex, n (%)
Female 146 (20.9)
Male 553 (79.1)
Race, n (%)
Caucasian 588 (84.2)
Black 73 (10.5)
Asian 12 (1.7)
Inuit 10 (1.4)
Other 15 (2.2)
Mode of HIV exposure, n (%)
MSM 299 (42.8)
Heterosexual 204 (29.2)
IV drug use 147 (21.0)
Other 28 (4.0)
Unknown 21 (3.0)
Hepatitis C co-infected, n (%)
Yes 191 (27.3)
No 508 (72.7)
History of AIDS, n (%)
Yes 236 (33.8)
No 463 (66.2)
Years since entering DHCS
a,
(interquartile range)
3.30 (1.18–7.01)
On HAART, n (%)
Yes 403 (57.7)
No 296 (43.3)
Median current CD4+ cell count
b,
cells/ml (interquartile range)
281 (117–462)
Median days since last CD+ cell
count measurement, (interquartile range)
47 (17–87)
Nadir CD4+ cell count, cells/ml
(interquartile range)
139 (48–240)
Median HIV RNA
a, log(copies/ml),
(interquartile range)
On HAART 1.6 (1.3–4.1)
HAART-naı ¨ve 4.6 (4.0–5.0)
Median days since last HIV RNA
measurement, (interquartile range)
48 (19–85)
Charlson Comorbidity Index score, n (%)
0–1 532 (76.1)
$2 167 (23.9)
aDHCS: Danish HIV Cohort Study.
bLast measurement before date of pneumonia.
doi:10.1371/journal.pone.0007022.t001
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However, our study is the first to show that HAART use also affects
prognosis in the presence of a pneumonia-related hospitalization.
The strengths of our study include use of a population-based,
nationwide cohort with nearly complete inclusion and minor loss
to follow-up; access to complete hospitalization data and vital
statistics; and availability of electronically collected longitudinal
data on viral load and CD4+ cell counts. The quality of the data
minimized selection and information biases. Because we consid-
ered only the first hospitalization for pneumonia, our estimates
were not biased by multiple pneumonia episodes occurring in
highly susceptible individuals.
Figure 1. Mortality after first hospitalization for pneumonia among persons with HIV by time period.
doi:10.1371/journal.pone.0007022.g001
Table 2. Short- and long-term impact of pneumonia on mortality among all HIV–infected individuals.
No of deaths Follow-up
a MR
b Crude MRR ratio Adjusted
c MRR
At any time after first hospitalization for pneumonia 263 3,131 0.23 (0.20–0.26) 3.56 (3.09–4.10) 2.79 (2.40–3.26)
Day 0–90 after admission 84 159 1.44 (1.17–1.79) 20.5 (16.3–25.7) 5.38 (4.27–6.78)
Day 91–365 after admission 54 420 0.35 (0.27–0.46) 4.98 (3.77–6.57) 1.80 (1.36–2.37)
Day 366+ after admission 125 2,552 0.13 (0.11–0.16) 1.90 (1.57–2.30) 1.62 (1.32–2.00)
No previous pneumonia 691 26,775 0.07 (0.07–0.08) 1 (ref) 1 (ref)
aIn years.
bPer 1000 days.
cAdjusted for use of HAART, history of AIDS, years since entering the DHCS, Charlson Comorbidity Index score, age, and current CD4+ cell count.
doi:10.1371/journal.pone.0007022.t002
Table 3. Causes of death among HIV patients with and without pneumonia.
HIV-related
a Serious non-AIDS conditions
b Unnatural
c Other/unknown No of deaths
Day 0–90 after pneumonia, n (%) 52 (61.9) 15 (17.9) 2 (2.4) 15 (17.9) 84 (100)
Day 91–365 after pneumonia, n (%) 29 (53.7) 7 (13.0) 3 (5.6) 15 (27.8) 54 (100)
Day 366+ after pneumonia, n (%) 36 (28.8) 36 (28.8) 5 (4.0) 48 (38.4) 125 (100)
No previous pneumonia, n (%) 296 (42.8) 145 (21.0) 42 (6.1) 208 (30.1) 691 (100)
aAIDS-defining illnesses and bacterial infections.
bCardiovascular disease [i.e. myocardial infarction or stroke], end stage renal and liver disease, COPD, and non-AIDS-defining malignancies.
cI.e. drug overdose, suicide, and accident.
doi:10.1371/journal.pone.0007022.t003
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have found identifiable bacterial pathogens in 24%–38% of HIV-
infected patients with pneumonia [13,14]. As data on specific
pathogens were not available, we do not know the percentage of
pneumonia cases in our study population caused by bacteria and
how this may have affected prognosis. Second, causes of death
registered in DHCS were based on information extracted from
medical records. Thus the exact cause of death may be uncertain
or, in some cases, multifactorial. For this reason we chose to group
causes of death into broader categories to determine whether HIV
was the key factor. We were unable to adjust for use of
opportunistic infection prophylaxis, smoking status, and/or
pneumococcal vaccination status since these data were not
available in DHCS database. Our results are restricted to
inpatients. Finally, despite our efforts to control for potential
confounders, it is possible that the observed protective effect of
HAART was due to confounding by indication (i.e., patients on
HAART had an a priori reduced risk of death for example due to a
healthier lifestyle compared to HAART-naı ¨ve patients).
The incidence rates of pneumonia in HIV-infected individuals
decreased from 51 hospitalizations per 1000 person-years during
1995–1996 to 20 hospitalizations per 1000 person-years during
2005–2007 [7]. In our study population, 30-day mortality did not
change over calendar time and was comparable to the mortality
risk of 6%–8% following pneumonia found in other studies of
HIV-infected persons [6,13], and consistent with the finding that
most pneumonia-related deaths occur within 30 days of hospital
admission [15].
Contrary to studies on invasive pneumococcal disease [16], we
found a decline in 90-day mortality from the pre-HAART era to
the HAART era. We even may have underestimated the decline in
mortality over calendar time because the median age in our cohort
increased from 1995 to 2008. Therefore, while the acute course of
pneumonia has change little over time, the reduction in 90-day
mortality may be due to reduced risk of death from sequelae
following the initial episode of pneumonia [17], perhaps stemming
from a general improvement in immune function after introduc-
tion of HAART.
In a study of non-HIV infected individuals aged 40–64
hospitalized for the first time with pneumonia, 30-day mortality
was 7.8%, and 90-day mortality was 11.6% [18]. These estimates
are comparable to what we found in HIV-infected individuals.
Table 4. Prognostics factors associated with 30-day mortality after first hospitalization for pneumonia among HIV–infected
individuals.
30 day mortality
n Deaths Mortality (%) OR (95% CI) p ORadj (95% CI)
a Coefficient (SE) p
Intercept 27.29 (1.11)
Age (per 10 year increase) 699 45 6.4 1.47 (1.13–1.90) 0.004 1.53 (1.11–2.12) 0.43 (0.17) 0.010
CD4+ cell count
b ,200 cells/ml No 411 16 3.9 1 (ref) 1 (ref) 0 (ref)
Yes 241 27 11.1 3.11 (1.64–5.91) 0.001 2.72 (1.28–5.78) 1.00 (0.38) 0.009
missing data 47 2 4.3 1.10 (0.24–4.93) 0.904 1.50 (0.29–7.74) 0.40 (0.84) 0.631
Charlson Comorbidty index 0–1 532 20 3.8 1 (ref) 1 (ref) 0 (ref)
$2 167 25 15.0 4.51 (2.43–8.35) ,0.001 4.07 (2.03–8.17) 1.40 (0.36) ,0.001
History of AIDS No 236 18 3.9 1 (ref) 1 (ref) 0 (ref)
Yes 463 27 11.4 3.19 (1.72–5.93) ,0.001 2.78 (1.34–5.78) 1.02 (0.37) 0.006
On HAART Yes 347 17 4.9 1 (ref) 1 (ref) 0 (ref)
No 352 28 7.9 1.68 (0.90–3.12) 0.103 3.19 (1.42–7.16) 1.16 (0.41) 0.005
Sex Female 146 3 2.0 1 (ref) 1 (ref) 0 (ref)
Male 553 42 7.6 3.92 (1.20–12.8) 0.024 3.86 (1.05–14.2) 1.35 (0.66) 0.042
Race Non-caucasian 111 5 4.5 1 (ref) 1 (ref) 0 (ref)
Caucasian 588 40 6.8 1.55 (0.60–4.01) 0.369 0.47 (0.16–1.43) 20.75 (0.57) 0.185
Calender period 1995–1996 152 12 7.9 1 (ref) 1 (ref) 0 (ref)
1997–2008 547 33 6.0 0.75 (0.38–1.49) 0.409 0.61 (0.23–1.57) 20.50 (0.49) 0.305
Hepatitis C co-infected No 31 6.1 1 (ref) 1 (ref) 0 (ref)
Yes 14 7.3 1.22 (0.63.2–34) 0.556 1.58 (0.74–3.39) 0.46 (0.39) 0.240
Mode of HIV exposure Non-IDU 552 35 6.3 1 (ref)
IDU 147 10 6.8 1.08 (0.52–2.23) 0.839 … … …
699 45 6.4 0.78 (0.61–0.99) 0.046 … … …
Nadir CD4+ cell count
(per 100 cells/mld e c r e a s e )
HIV RNA, (per log10 increase
in copies/ml)
b
On HAART 403 24 6.0 2.76 (0.40–19.2) 0.304 … … …
HAART-naı ¨ve 296 21 7.1 0.36 (0.02.5.57) 0.468 … … …
aThis logistic regression model is adjusted for all variables in the table except: IDU as mode of HIV exposure which is interdependent to hepatitis C status, Nadir CD4+
cell count which is interdependent to AIDS and HIV RNA which is interdependent to use of HAART.
bLast measurement before date of pneumonia. adj=Adjusted; OR=Odds Ratio; CI=Confidence Interval.
doi:10.1371/journal.pone.0007022.t004
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hospitalization pneumonia was similar to the increased risk
recently reported for ‘‘mild’’ AIDS-defining events (i.e., pulmonary
and extrapulmonary tuberculosis, pneumocystis jiroveci (carinii)
pneumonia and esophageal candidiases) [19].
Others have found a four to five-fold increased risk of death
(follow-up #51 months) among HIV-infected persons with
pneumonia, compared to those without pneumonia [6,13], which
is in accordance with our findings. Contrary to other studies [20],
however, we found that the increased risk of death persisted
beyond one year. Although unmeasured confounding factors
cannot be ruled out as a contributory cause of the increased long
term risk of death, pneumonia could also be viewed as a marker of
immune system frailty that may not be reflected by the CD4+ cell
count.
We found that HAART use improved the prognosis after a
pneumonia-related hospitalization also after adjusting for CD4+
cell count, which is in line with results from earlier studies
[21,22,23]. In a CD4+ cell-count-adjusted subgroup analysis from
the Strategies for Management of Antiretroviral Therapy
(SMART) trial, the risk of opportunistic diseases and death was
increased in HAART-naı ¨ve patients or those off-HAART for 6
months compared to those with suppressed HIV viral load in
plasma [21]. In an observational study of asymptomatic HIV
patients with CD4+ counts of 351 to 500 cells/ml, deferring
HAART vs. initiating early HAART was associated with a
mortality ratio of 1.7 [23]. Brenchley and colleagues demonstrated
that microbial translocation and immune activation were higher
among HAART-naı ¨ve than those on HAART [24]. Whether
increased immune activation influences an individual’s ability to
survive a serious infection such as pneumonia remains to be
determined.
We observed a lower short term mortality among females than
males. In the HIV Epidemiologic Research (HER) Study on
pneumonia Kohli et al. found in-hospital mortality after bacterial
pneumonia to be 7.7% among females [6,7]. In our study, in
which only 20.9% of the subjects were females, 30 day mortality
was very low (2.0% compared to 7.6% for males). All-cause
mortality rates may be moderately lower among females than
males with HIV [4], but the considerable effect of gender on short
term mortality found in our study may have been caused by
chance and should be interpreted with caution.
In conclusion, a first hospitalization for pneumonia in HIV-
infected individuals predicted an increased risk of death beyond
one year. Among those hospitalized with pneumonia, use of
HAART was associated with a reduced risk of death, independent
Table 5. Prognostics factors for 90-day mortality after first hospitalization for pneumonia among HIV–infected individuals.
90 day mortality
n Deaths Mortality (%) OR (95% CI) p ORadj (95% CI)
a Coefficient (SE) p
Intercept 26.82 (1.01)
Age (per 10 year increase) 699 84 12.0 1.36 (1.11–1.66) 0.003 1.43 (1.11–1.85) 0.36 (0.13) 0.007
CD4+ cell count
b ,200 cells/ml No 411 28 6.8 1 (ref) 1 (ref) 0 (ref)
Yes 241 49 20.3 3.49 (2.13–5.73) ,0.001 2.52 (1.37–4.65) 0.93 (0.31) 0.003
missing data 47 7 14.9 2.39 (0.98–5.83) 0.055 1.91 (0.67–5.43) 0.65 (0.53) 0.223
Charlson Comorbidty index 0–1 532 44 8.2 1 (ref) 1 (ref) 0 (ref)
$2 167 40 24.0 3.49 (2.18–5.59) ,0.001 3.86 (2.19–6.78) 1.35 (0.29) ,0.001
History of AIDS No 236 35 7.6 1 (ref) 1 (ref) 0 (ref)
Yes 463 49 20.8 3.20 (2.01–5.11) ,0.001 2.46 (1.40–4.32) 0.90 (0.29) 0.002
On HAART Yes 347 25 7.2 1 (ref) 1 (ref) 0 (ref)
No 352 59 16.8 2.59 (1.58–4.25) ,0.001 3.58 (1.83–6.99) 1.27 (0.34) ,0.001
Sex Female 146 5 3.4 1 (ref) 1 (ref) 0 (ref)
Male 553 79 14.3 4.40 (1.79–10.9) 0.001 3.77 (1.37–10.4) 1.33 (0.52) 0.010
Race Non-caucasian 111 5 4.5 1 (ref) 1 (ref) 0 (ref)
Caucasian 588 79 13.4 3.29 (1.30–8.32) 0.012 1.15 (0.41–3.24) 0.14 (0.53) 0.791
Calender period 1995–1996 152 34 22.4 1 (ref) 1 (ref) 0 (ref)
1997–2008 547 50 9.1 0.35 (0.22–0.56) ,0.001 0.80 (0.39–1.64) 20.22 (0.36) 0.548
Hepatitis C co-infected No 508 63 12.4 1 (ref) 1 (ref) 0 (ref)
Yes 191 21 11.0 0.87 (0.52–1.47) 0.610 1.13 (0.61–2.11) 0.12 (0.32) 0.701
Mode of HIV exposure Non-IDU 552 66 12.0 1 (ref)
IDU 147 8 12.3 1.03 (0.59–1.79) 0.924 … … …
Nadir CD4+ cell count
(per 100 cells/ml decrease)
699 84 12.0 1.38 (1.13–1.69) 0.002 … … …
HIV RNA, (per log10 increase
in copies/ml)
b
On HAART 403 39 9.2 2.27 (0.43–12.1) 0.337 … … …
HAART-naı ¨ve 296 45 14.9 0.24 (0.03–2.18) 0.206 … … …
aThis logistic regression model was adjusted for all variables in the table except: IDU as mode of HIV exposure which is interdependent to hepatitis C status, Nadir CD4+
cell count which is interdependent to AIDS and HIV RNA which is interdependent to use of HAART.
bLast measurement before date of pneumonia. adj=Adjusted; OR=Odds Ratio; CI=Confidence Interval.
doi:10.1371/journal.pone.0007022.t005
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acquisition of pneumonia is a marker of frailty, the latter may
indicate that this frailty can be partly offset by use of HAART.
These findings support the need for additional research to assess
the role of HAART in reducing morbidity and mortality
associated with non-AIDS-defining infections. Promotion of early
HAART initiation may not only lead to reduced mortality after
pneumonia, it may also reduce the risk of acquiring pneumonia
severe enough to require hospitalization [6,7]. Finally, it is
reassuring that the prognosis following pneumonia has improved
over calendar time.
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